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Background: Anxiety and depression are prevalent in patients with asthma, and associated
with more exacerbations and increased health care utilization. Since psychiatric intervention
might improve asthma control, we examined whether patients with severe, prednisone-
dependent asthma are at higher risk of these disorders than patients with severe non-
prednisone dependent asthma or mild-moderate asthma, and whether they exhibit different
personality traits.
Methods: Sixty-seven adults with severe prednisone-dependent asthma, 47 with severe non-
prednisone dependent and 73 patients with mild-moderate asthma completed the HADS
depression and anxiety subscale and the NEO-FFI for personality traits. In addition, asthma
duration, body mass index and FEV1 were measured.
Results: The prevalence of clinically significant depressive symptoms (9% vs. 0 vs. 0%;
pZ 0.009) and anxiety symptoms (19% vs. 6.4 vs. 5.5%; pZ 0.01), was higher in patients with
severe, prednisone-dependent asthma than in patients with severe non-prednisone dependent
or mild-moderate asthma. Patients with prednisone-dependent asthma were respectively 3.4iratory volume in one second; HADS, hospital anxiety and depression scale; HADS-A, hospital anxiety
, hospital anxiety and depression scale depression; NEO-FFI, NEO-Five-Factor Inventory; BMI, body
rd deviation; OCS, oral corticosteroids; CS, inhaled corticosteroids; LABA, long acting beta agonist.
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Depression and anxiety in asthma 439(95%CI: 1.0e10.8 p Z 0.04) and 3.5 (95%CI: 1.3e9.6 p Z 0.01) times more likely to have sig-
nificant depression symptoms and 1.6 (95%CI: 0.7e3.7, p Z 0.2) and 2.5 (95%CI: 01.1e5.5,
p Z 0.02) times more likely to have symptoms of anxiety than patients with severe non-
prednisone dependent or mild-moderate asthma. There were no differences found in person-
ality traits between the 3 groups.
Conclusion: Patients with severe, prednisone-dependent asthma have more often psychologi-
cal distress as compared to patients with severe non-prednisone dependent or mild-moderate
asthma.
ª 2014 Published by Elsevier Ltd.Introduction
Mental disorders, including anxiety and depression are
more prevalent in asthma as compared to the general
population [1e8]. Although there is a clear relationship
between anxiety, depression and asthma, the association
with asthma severity is controversial. Some studies have
shown significant differences in anxiety [9] and depression
[10] in patients with severe asthma as compared to those
with milder disease, while other studies did not find such
differences [11e13].
Although these results are inconsistent, it has been
clearly demonstrated that psychiatric morbidity in asthma
is associated with reduced adherence to treatment [14],
loss of asthma control [10,15], increased medical con-
sumption [16] and increased exacerbations requiring bursts
of oral corticosteroids [17,18]. Moreover, it has been shown
that depression in chronic diseases such as asthma, has a
greater effect on general health than depression or asthma
alone [7].
Patients who use chronic oral corticosteroids are at
higher risk of developing psychiatric comorbidities [19,20].
In patients with severe, prednisone-dependent asthma this
may be bi-directional. On the one hand, the use of oral
corticosteroids in severe asthma may lead to higher levels
of anxiety and depression; while on the other hand, the
underlying psychopathology may lead to less asthma con-
trol and thereby more prednisone dependence. Patients
with steroid-dependent asthma seem therefore to be at
highest risk of developing depression and anxiety disorders,
and might benefit most from psychiatric interventions that
contribute to asthma control.
In addition to anxiety and depression, specific person-
ality traits have been associated with disease severity and
poor outcome. Patients with near-fatal asthma have been
shown to have less adaptive personality characteristics
[15], and patients with severe asthma according to ATS
criteria [21] appeared to have maladaptive coping styles
[13] as compared to patients with milder disease. There are
no reports comparing other personality traits between pa-
tients with mild-moderate and severe asthma.
Therefore, the aim of the present study was to investi-
gate the prevalence of anxiety and depression symptoms in
patients with severe, prednisone-dependent asthma and to
investigate whether these patients have elevated
dysfunctional personality traits as compared to patients
with severe, non-prednisone dependent and mild-moderate
disease. If so, this might have important implications for
the management of patients with this disabling disease.Methods
Patients
Adult patients (18e80 yr) were recruited from the outpa-
tient departments of 2 academic and 3 non-academic
teaching hospitals in The Netherlands. Patients with mild-
moderate asthma had to have a history of episodic dyspnea
and wheezing, a documented reversibility in forced expi-
ratory volume in 1 s (FEV1) of >12% predicted [22] or
hyperresponsiveness to histamine (PC20 < 8 mg/ml) [23].
Patient with severe asthma and prednisone-dependent and
non-prednisone-dependent asthma had to meet the ATS
criteria of severe asthma [21]. In addition, patients with
prednisone dependent asthma were on maintenance ther-
apy with prednisone (2.5 mg/day) for at least three
months. Current smokers and patients with a smoking his-
tory of more than 15 packyears were excluded. The study
was approved by the Leiden University Medical Centre
Hospital Medical Ethics Committee and all patients gave
written informed consent (P06.191).
Design
In this cross-sectional study all patients with asthma were
asked to participate at their visit to the pulmonary outpa-
tient clinics for a regular doctor’s appointment.
In one visit, patients’ characteristics were documented
according to a structured questionnaire. Then the patients
completed the 2 self-report questionnaires on psychological
functioning. Finally, postbronchodilator FEV1 was assessed
using a handheld spirometer (Ferraris Respiratory Piko-1)
according to ERS criteria [22].
Psychological questionnaires
The Hospital Anxiety and Depression Scale (HADS) is a
widely used screening questionnaire to identify possible
and probable cases [24] of depression (HADS-D) and anxiety
(HADS-A) [25], which is reliable in patient and healthy
populations [24]. The questionnaire contains 7 anxiety and
7 depression questions, each scoring 0e3 points. A cut off
score of 11 points was used to define a probable case of
anxiety or depression [26].
The NEO-Five-Factor Inventory (NEO-FFI) contains 60
multiple choice questions with a score ranging 1e5 for each
answer. The questionnaire measures the 5 leading di-
mensions of the Big Five-model [27], neuroticism
440 M. Amelink et al.(emotional stability vs. lability), openness (susceptibility to
new experiences), extraversion (out- or inwards directed
energy and orientation), agreeableness (orientation to-
wards others) and conscientiousness (conscience towards
own behavior). In the present study the authorized Dutch
translations were used for all questionnaires.
Statistical analysis
Demographic and psychopathological differences between
patients with severe, prednisone-dependent asthma, non-
prednisone dependent asthma and mild-moderate asthma
were analyzed using one-way anova, chi-square tests and
kruskall wallis tests. The sum scores obtained on the anxi-
ety (HADS-A), depression (HADS-D), neuroticism, openness,
extraversion, agreeableness and conscientiousness sub-
scales (NEO-FFI) were analyzed as continuous variables.
Potential factors associated with anxiety and depression
were analyzed as dichotomous independent variables, using
the following contrasts: HADS-D 11 vs. <11, HADS-A 11
vs. <11, asthma duration 15 yr vs. <15 yr (median) and
BMI 28 vs. <28 (median), age 49 vs.<49 (median). Odds
ratios for anxiety and depression as reference group were
obtained by logistic regression analyses.
Asthma duration was defined as the number of years
since asthma diagnosis. Number of smoking packyears was
calculated by defining 1 packyear of smoking 20 cigarettes/
day for a whole year. Chronic use of oral corticosteroids
was defined as the daily use of prednisone for at least 1
month before entering the study. Analyses were performed
using SPSS version 16.0 (SPSS, Inc., Chicago, IL). p-Values
less than 0.05 were considered significant.
Power
As a clinical meaningful difference on the HADS scale we
defined a 2 unit difference. Because the HADS has a stan-
dard deviation of 425, we needed to include 128 patients inTable 1 Baseline characteristics of patients with severe pre
moderate asthma.
Prednisone-dependent
n Z 67
Age (yr)a 49.6 (12.9)
Female gender % 58.2
Asthma duration (yr)b 21 (9e36)
BMIa 28.2 (5.6)
Ex-smoker % 43.3
Packyearsb 0 (0e4.1)
Atopy% 54.5
OCS dose (mg/day)b 10 (5e15)
Duration of daily OCS (mth) 44 (3e360)
ICS dose (mg/day)b 1000 (625e1250)
LABA% 100
pbFEV1 81.0 (23.5)
BMI, body mass index; OCS, oral corticosteroids; ICS, inhaled cortic
pbFEV1, forced expiratory volume in 1 s postbronchodilator.
a Mean (SD).
b Median (range).total to achieve 80% power for this medium effect size
(significance level 0.05). As a clinical meaningful difference
on the NEO-FFI scale we defined a 3 unit difference.
Because the NEO-FFI has a standard deviation of 627, we
needed to include 128 patients in total to achieve 80%
power for this medium effect size (significance level 0.05).
Results
Patient characteristics
One-hundred-eighty-seven patients, 67 patients with se-
vere, prednisone-dependent asthma (20e77 yr), 47 with
severe non-prednisone dependent asthma (19e70 yr) and
73 patients with mild-moderate asthma (18e75 yr) partic-
ipated in the study. There was no significant difference
between the prednisone-dependent patients and the group
of severe, non-prednisone dependent patients and mild-
moderate asthma patients with respect to gender, BMI and
atopy (Table 1). However, prednisone-dependent asthma
patients were older, had longer asthma duration and
showed more severe airflow limitation as compared to the
other patients.
Psychological characteristics in prednisone-
dependent vs. severe non-prednisone dependent
and mild-moderate asthma
Patients with severe prednisone-dependent asthma had
significant higher scores on depression symptoms (HADS-D
mean (SD) 4.5 (3.6) vs. 2.4 (2.4) and 3.4 (2.5), p Z 0.002)
and showed a trend towards higher anxiety symptoms
(HADS-A 6.2 (4.4) vs. 4.8 (3.6) and 5.0 (2.9), p Z 0.06) as
compared to patients with severe or milder disease resp.
(Table 2).
The prevalence of clinically significant depressive
symptoms (HADS-D score 11) and anxiety symptomsdnisone-dependent asthma vs. moderate-severe and mild-
Severe non-prednisone
dependent n Z 47
Mild-moderate
n Z 73
p-Value
40 (16.5) 46.6 (15) 0.003
53.2 60.3 0.7
16 (5e21.8) 10 (2e27) 0.005
26.5 (5.4) 26.1 (4.8) 0.07
17 37 0.01
0 (0e0) 0 (0e3.3) 0.013
66.7 60.7 0.4
0 (0e0) 0 (0e0) <0.001
0 (0e0) 0 (0e0) <0.001
750 (500e1500) 250 (250e500) <0.001
91.5 68.5 <0.001
96 (23.6) 102.4 (14.3) <0.001
osteroids fluticason equivalent; LABA; long acting beta agonist,
Table 2 Psychological Questionnaire scores for patients with severe prednisone-dependent, moderate-severe and mild-
moderate asthma.
Prednisone-dependent
n Z 67
Severe non-prednisone
dependent n Z 47
Mild-moderate
n Z 73
p-Value
HADS Anxiety 6.2 (4.4) 4.8 (3.6) 5.0 (2.9) 0.07
Depression 4.5 (3.6) 2.5 (2.4) 3.4 (2.5) 0.002
NEO-FFI Neuroticism 33.7 (5.6) 32.2 (3.9) 31.8 (2.8) 0.07
Extraversion 38.6 (4.7) 39 (4.1) 39 (3.6) 0.8
Openness 37.4 (4.2) 36.4 (4.2) 37.4 (3.3) 0.3
Agreeableness 35 (4.3) 36 (5.2) 35.8 (4.5) 0.4
Conscientiousness 40.2 (4.3) 39.9 (4.1) 40.8 (3.1) 0.4
Values expressed in mean (SD); HADS, Hospital Anxiety and Depression Scale; NEO-FFI, Neo-Five-Factor Inventory.
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prednisone dependent asthma than in patients with severe
non-prednisone-dependent or mild-moderate asthma (9%
vs. 0% and 0%; p Z 0.004) and (19% vs. 6.4% and 5.5%;
p Z 0.01), respectively (Fig 1). There were no differences
in personality traits between the three groups (Table 2).
Logistic regression analyses showed that patients with
prednisone-dependent asthma were respectively 3.4 (95%
CI: 1.0e10.8 p Z 0.04) and 3.5 (95%CI: 1.3e9.6 p Z 0.01)
times more likely to have clinically significant symptoms of
depression as compared to non-prednisone dependent se-
vere asthma and mild-moderate asthma. In addition, as
compared to mild-moderate asthma, patients with
prednisone-dependent asthma were 2.5 (95%CI: 01.1e5.5,
pZ 0.02) times more likely to have significant symptoms of
anxiety and 1.6 (95%CI: 0.7e3.7, pZ 0.2) times more likely
as compared to non-prednisone dependent severe asthma,
although the latter one was not significant. In addition,
there were no associations found between depression or
anxiety and age, asthma duration, BMI, smoking history and
dose of OCS. Also, there was no association found between
the dose of prednisone and anxiety or depression.
Discussion
In the present study we found a higher prevalence of psy-
chological distress (depression and anxiety) in patients withFigure 1 Percentage of patients with high anxiety and
depression symptoms in severe prednisone-dependent asthma
as compared to patients with severe non-prednisone depen-
dent asthma and mild asthma.severe, prednisone-dependent asthma as compared to pa-
tients with severe, non-prednisone dependent or mild-
moderate disease. Patients with prednisone-dependent
asthma were 3.5 times more likely to have clinically sig-
nificant depression symptoms, and about 2.5 times more
likely to have significant anxiety symptoms as compared to
patients with severe or mild-moderate disease. With
respect to personality traits we found no differences in
patients with severe, prednisone-dependent asthma and
the other groups. This implies that this particular group of
patients with prednisone-dependent asthma should be
screened routinely for anxiety and depression symptoms
and offered psychiatric care if needed.
The present study is the first, to our knowledge, to
systematically investigate psychological distress and per-
sonality traits in patients with severe, prednisone-
dependent asthma as compared to less severe, non-
prednisone dependent asthma. Previous studies have
investigated the prevalence of depression or anxiety
symptoms (HADS score >11) in asthma irrespective of dis-
ease severity. They found prevalences ranging from 10 to
13.6% and 9e31.6% respectively [18,28,29].
The non-prednisone dependent asthma patients in our
study had HADS-A and HADS-D scores similar to that of the
general population [25,30]. However, patients with severe
prednisone-dependent asthma had higher scores, similar to
those of (non-psychiatric) medical outpatients [25]. This
indicates that the prevalence of anxiety and depression
symptoms in severe prednisone-dependent asthma is high,
but not higher than in other outpatients. The prevalence of
anxiety and depression in severe non-prednisone depen-
dent asthma and mild-moderate asthma is within the
normal range.
Studies that compared the prevalence of anxiety and
depression between patients with severe and milder forms
of asthma found conflicting results. Several studies showed
no differences between patients with severe and mild-
moderate asthma [11e13], while other studies found higher
levels of psychopathology in patients with more severe
disease [31e33]. The present study sheds new light on
these conflicting findings by showing that only prednisone-
dependent severe asthma patients have more anxiety and
depression, which suggests that these psychological condi-
tions are associated with prednisone treatment rather than
with disease severity per se.
With respect to personality traits, relatively few studies
have been performed in severe asthma. Several studies
442 M. Amelink et al.found that patients with severe asthma [13] and near-fatal
asthma [15] show less adaptive personality characteristics
as compared to those with milder disease, although this
relationship was not always found [12]. In these studies
different methods were used to measure personality traits,
and therefore the results are difficult to interpret. One
study investigated the “Big 5” personality profile in a Por-
tuguese asthma population [34]. Neuroticism scores were
positively associated with asthma severity, which is
consistent with the trend we found in our study. They also
found extraversion and openness scores to be lower with
increasing asthma severity, which we did not find. Inter-
estingly, all patients with asthma in our study had relatively
low scores on conscientiousness and very low scores on
agreeableness as compared to the general population [35],
for which we have no explanation. Obviously, more studies
are needed to further investigate the relationship between
personality traits and asthma severity.
The causality of the association between prednisone
dependent asthma and anxiety and depression, might be bi-
directional. The most likely explanation is that depression
and possibly anxiety are a direct effect of corticosteroid
treatment. One study found an association between the use
of inhaled corticosteroids and depressive symptoms [36]
and it has been shown that patients taking (long term)
prednisone therapy tend to show higher scores on psychi-
atric symptoms [19,37,38]. This result is consistent with the
observation of an increased prevalence of psychopathology
in patients with long-term cured Cushing’s disease, sug-
gesting irreversible effects of previous glucocorticoid
excess on the central nervous system [39].
Alternatively, psychological stress might be the cause of
prednisone-dependency in patients with asthma. Psycho-
logical distress has been shown to be associated with more
severe asthma symptoms [40], increased health care utili-
zation [16], and frequent exacerbations [17] requiring oral
corticosteroid bursts. It could be speculated that psycho-
logical stress leads to increased perception of asthma
symptoms or even more severe airway inflammation [41],
which may the cause of failure to control asthma with
inhaled medications alone or to discontinue oral cortico-
steroids after an acute exacerbation.
Finally, psychosocial stress could be the consequence of
chronic severe asthma itself. The experience of frequent
asthma attacks and/or chronic impairment in social func-
tioning might obviously result in anxiety and depression [42].
However, our results show an association with prednisone
dependent asthma and not with severe non-prednisone
dependent asthma. Therefore, this explanation is the least
likely.
Although this study was performed in a well-defined group
of patients and was adequately powered, it might have some
limitations. Thedesignof thepresent study is cross-sectional;
thereforewecannot be certain that the results are consistent
over time. Asthma as well as anxiety and depression are
conditions with variable degrees of symptoms, and consis-
tencyover time in thesepatientshasneverbeen investigated.
Nevertheless, theHADShasbeenwell validated in thegeneral
population, in general practice and in psychiatric patients
[26]. In addition, the HADS has proven to be adequate for
repeated assessment of probable anxiety and depression at
subsequent visits for follow-up [26].Second, patients had to use prednisone on a daily basis
for at least one month. It could be speculated that, if
anxiety and depression are adverse effects of oral corti-
costeroids, this period may be too short. However, at least
one study showed that anxiety and depression can develop
within 5 days after starting oral corticosteroids [19]. In
addition, the vast majority of our patients used chronic oral
prednisone for many years. Therefore, we do not think this
influenced the results of the present study.
The results of the present study have clinical and
research implications. Physicians should be aware that oral
corticosteroids may induce psychiatric adverse effects,
such as anxiety and depression which may in turn influence
asthma severity and control. Therefore, it might be worth
to screen patients with severe prednisone-dependent
asthma for anxiety and depression symptoms. In short-
term intervention studies promising effects of pharmaceu-
tical or psychosocial interventions have been observed
[43,44], but more prospective studies are needed in this
category of patients to see if better asthma control or less
oral corticosteroid-dependency can be obtained on the long
term.
In conclusion, we found significantly more anxiety and
depression symptoms in patients with severe prednisone-
dependent asthma as compared to patients with non-
steroid dependent severe asthma or mild-moderate
asthma. Patients with prednisone dependent asthma are
3.5 times more likely to have significant symptoms of
depression and 2 times more likely to have significant
symptoms of anxiety than their non-steroid dependent
counterparts. Therefore, these patients deserve to be
screened for depression and anxiety, and offered psychi-
atric or psychosocial care if needed. Hopefully, such in-
terventions will lead to better control of the disease and
less need for oral corticosteroids.
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